SLV310, a molecule combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition

被引：0
|
作者：
Kruse, CG [1 ]
Tuinstra, T [1 ]
Herremans, A [1 ]
van Vliet, B [1 ]
Long, SK [1 ]
van der Heijden, JA [1 ]
Hesselink, MB [1 ]
机构：
[1] Solvay Pharmaceut, Res Labs, Weesp, Netherlands
来源：
SCHIZOPHRENIA RESEARCH | 2003年 / 60卷 / 01期
关键词：
D O I：
10.1016/S0920-9964(03)80853-8
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：110 / 110
页数：1
相关论文
共 50 条
  • [31] Differential effects of dopamine D1 and D2/3 receptor antagonism on motor responses
    Steven Tran
    Magda Nowicki
    Arrujyan Muraleetharan
    Robert Gerlai
    Psychopharmacology, 2015, 232 : 795 - 806
  • [32] Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia
    Rotella, David P.
    McFarlane, Geraldine R.
    Greenfield, Alexander
    Grosanu, Cristina
    Robichaud, Albert J.
    Denny, Rajiah Aldrin
    Feenstra, Rolf W.
    Nunez-Garcia, Sara
    Reinders, Jan-Hendrik
    van der Neut, Martina
    McCreary, Andrew
    Kruse, Chris G.
    Sullivan, Kelly
    Pruthi, Farhana
    Lai, Margaret
    Zhang, Jean
    Kowal, Dianne M.
    Carrick, Tikva
    Grauer, Steven M.
    Navarra, Rachel L.
    Graf, Radka
    Brennan, Julie
    Marquis, Karen L.
    Pausch, Mark H.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (19) : 5552 - 5555
  • [33] Differential effects of dopamine D1 and D2/3 receptor antagonism on motor responses
    Tran, Steven
    Nowicki, Magda
    Muraleetharan, Arrujyan
    Gerlai, Robert
    PSYCHOPHARMACOLOGY, 2015, 232 (04) : 795 - 806
  • [34] Chronic Administration of the D2 Receptor Agonist Pramipexole Enhances Serotonin and Dopamine Neurotransmission
    Chernoloz, Olga
    El Mansari, Mostafa
    Blier, Pierre
    BIOLOGICAL PSYCHIATRY, 2010, 67 (09) : 241S - 242S
  • [35] Novel and Potent Dopamine D2 Receptor Go-Protein Biased Agonists
    Bonifazi, Alessandro
    Yano, Hideaki
    Guerrero, Adrian M.
    Kumar, Vivek
    Hoffman, Alexander F.
    Lupica, Carl R.
    Shi, Lei
    Newman, Amy Hauck
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2019, 2 (01) : 52 - 65
  • [36] Effect of dopamine D2 receptor and serotonin 2A receptor gene polymorphisms on response to risperidone in schizophrenia
    Goud, A. Charanraj
    Shewade, D. G.
    Kumar, R. Raj
    Surendiran, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S958 - S959
  • [37] Mutational and biochemical analysis of dopamine in dystonia -: Evidence for decreased dopamine D2 receptor inhibition
    Todd, RD
    Perlmutter, JS
    MOLECULAR NEUROBIOLOGY, 1998, 16 (02) : 135 - 147
  • [38] Antagonism of dopamine D2 receptor/β-arrestin 2 interaction is a common property of clinically effective antipsychotics
    Masri, Bernard
    Salahpour, Ali
    Didriksen, Michael
    Ghisi, Valentina
    Beaulieu, Jean-Martin
    Gainetdinov, Raul R.
    Caron, Marc G.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (36) : 13656 - 13661
  • [39] Typical and atypical antipsychotics do not differ markedly in their reversibility of antagonism of the dopamine D2 receptor
    Sahlholm, Kristoffer
    Marcellino, Daniel
    Nilsson, Johanna
    Ogren, Sven Ove
    Fuxe, Kjell
    Arhem, Peter
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 (01): : 149 - 155
  • [40] Antagonism of the D2 dopamine receptor enhances tremor but reduces voluntary muscle activation in humans
    Thorstensen, Jacob R.
    Tucker, Murray G.
    Kavanagh, Justin J.
    NEUROPHARMACOLOGY, 2018, 141 : 343 - 352
12345